Figure 5
From: Runx2 regulates survivin expression in prostate cancer cells
Analysis of Runx2 and survivin expression in prostate cancer cells. (A) Protein expression in various human prostate cancer cell lines in comparison with immortalized normal prostate epithelial (MLC) and benign hyperplastic (BPH-1) cells. For each cell line approximately 40 μg of whole-cell lysates were assayed by Western blotting and actin served as loading control. (B) Examples of immunostaining in benign and malignant human prostate cancer tissues: (a, b) Survivin (case 1), strong staining of malignant epithelium relative to adjacent benign epithelium and stroma; (c, d) Survivin (case 2), similarly strong staining of malignant epithelium relative to benign epithelium and stroma; (e, f) Runx2 (case 1), moderate staining of malignant epithelium with weak stromal staining; (g, h) Runx2 (case 2), comparable moderate staining of malignant epithelium, with weak stromal staining. Benign epithelium displayed low-to-moderate staining: (a, c, e, g) magnification × 25 and (b, d, f, h) magnification × 100. (C) Correlation of Runx2 expression with tumor growth in the conditional Pten deletion mouse model of prostate cancer. Runx2 expression in the anterior prostate tissues of the knockout mice (KO) and in the corresponding normal prostate lobe of the littermate controls (c) were analyzed by Western blotting. The tissues were obtained from mice at age ranging from 1.6 to 11 months. (D) Detection of increased Runx2 expression by Western blotting in tumors from all the lobes from an 11-month old mouse as compared with its littermate control. AP, VP, DLP denote anterior, ventral, and dorsolateral lobes, respectively.
